Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387356823> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4387356823 abstract "Summary This open-label, phase 1/1b study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of fruquintinib in United States (U.S.) patients to confirm the recommended phase 2 dose (RP2D) established in China. Patients with advanced solid tumors who had progressed on approved systemic therapy, were enrolled into 2 successive dose escalation cohorts, fruquintinib 3 mg (n = 7) or 5 mg (n = 7), orally, once daily (QD), 3 weeks on and 1 week off (3/1) with a 3 + 3 design followed by a dose expansion cohort at the RP2D 5 mg dose (n = 6). PK samples were collected on Days 1, 14, and 21 (Cycle 1). One of 6 dose-limiting toxicity (DLT)-evaluable patients in the 3 mg cohort had a DLT of grade 4 hypertension; there were no DLTs in the 5 mg cohort. The RP2D was confirmed to be 5 mg QD 3/1. All 20 patients experienced a treatment-emergent adverse event; grade ≥ 3 in 5 (71.4%; 3 mg dose) and 12 (92.3%; 5 mg dose) patients. Two patients had a confirmed partial response. After single and multiple doses, median peak plasma concentrations occurred at 2 h post-dose. Steady-state was achieved after 14 days of QD dosing with systemic exposure four-fold higher than that after a single dose. Fruquintinib was well tolerated, and the safety and PK profile at the 5 mg RP2D in U.S. patients with advanced solid tumors was consistent with dose-finding studies in China. Preliminary anticancer activity was observed. This study is registered at Clinicaltrials.gov NCT03251378 ." @default.
- W4387356823 created "2023-10-06" @default.
- W4387356823 creator A5008330168 @default.
- W4387356823 creator A5010034986 @default.
- W4387356823 creator A5024388671 @default.
- W4387356823 creator A5048123926 @default.
- W4387356823 creator A5068695791 @default.
- W4387356823 creator A5070675863 @default.
- W4387356823 creator A5073864381 @default.
- W4387356823 creator A5081466882 @default.
- W4387356823 date "2023-10-05" @default.
- W4387356823 modified "2023-10-06" @default.
- W4387356823 title "Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States" @default.
- W4387356823 cites W1998028599 @default.
- W4387356823 cites W2007058673 @default.
- W4387356823 cites W2137591261 @default.
- W4387356823 cites W2434670966 @default.
- W4387356823 cites W2572177645 @default.
- W4387356823 cites W2810647922 @default.
- W4387356823 cites W2898603310 @default.
- W4387356823 cites W4293241248 @default.
- W4387356823 doi "https://doi.org/10.1007/s10637-023-01395-y" @default.
- W4387356823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37796398" @default.
- W4387356823 hasPublicationYear "2023" @default.
- W4387356823 type Work @default.
- W4387356823 citedByCount "0" @default.
- W4387356823 crossrefType "journal-article" @default.
- W4387356823 hasAuthorship W4387356823A5008330168 @default.
- W4387356823 hasAuthorship W4387356823A5010034986 @default.
- W4387356823 hasAuthorship W4387356823A5024388671 @default.
- W4387356823 hasAuthorship W4387356823A5048123926 @default.
- W4387356823 hasAuthorship W4387356823A5068695791 @default.
- W4387356823 hasAuthorship W4387356823A5070675863 @default.
- W4387356823 hasAuthorship W4387356823A5073864381 @default.
- W4387356823 hasAuthorship W4387356823A5081466882 @default.
- W4387356823 hasBestOaLocation W43873568231 @default.
- W4387356823 hasConcept C112705442 @default.
- W4387356823 hasConcept C126322002 @default.
- W4387356823 hasConcept C197934379 @default.
- W4387356823 hasConcept C2777288759 @default.
- W4387356823 hasConcept C2777334693 @default.
- W4387356823 hasConcept C2778375690 @default.
- W4387356823 hasConcept C29730261 @default.
- W4387356823 hasConcept C71924100 @default.
- W4387356823 hasConcept C72563966 @default.
- W4387356823 hasConcept C90924648 @default.
- W4387356823 hasConceptScore W4387356823C112705442 @default.
- W4387356823 hasConceptScore W4387356823C126322002 @default.
- W4387356823 hasConceptScore W4387356823C197934379 @default.
- W4387356823 hasConceptScore W4387356823C2777288759 @default.
- W4387356823 hasConceptScore W4387356823C2777334693 @default.
- W4387356823 hasConceptScore W4387356823C2778375690 @default.
- W4387356823 hasConceptScore W4387356823C29730261 @default.
- W4387356823 hasConceptScore W4387356823C71924100 @default.
- W4387356823 hasConceptScore W4387356823C72563966 @default.
- W4387356823 hasConceptScore W4387356823C90924648 @default.
- W4387356823 hasLocation W43873568231 @default.
- W4387356823 hasLocation W43873568232 @default.
- W4387356823 hasOpenAccess W4387356823 @default.
- W4387356823 hasPrimaryLocation W43873568231 @default.
- W4387356823 hasRelatedWork W1990197915 @default.
- W4387356823 hasRelatedWork W2087016115 @default.
- W4387356823 hasRelatedWork W2305775430 @default.
- W4387356823 hasRelatedWork W2427186628 @default.
- W4387356823 hasRelatedWork W2465571689 @default.
- W4387356823 hasRelatedWork W3166797618 @default.
- W4387356823 hasRelatedWork W3191427281 @default.
- W4387356823 hasRelatedWork W4244546467 @default.
- W4387356823 hasRelatedWork W4311628015 @default.
- W4387356823 hasRelatedWork W4312693609 @default.
- W4387356823 isParatext "false" @default.
- W4387356823 isRetracted "false" @default.
- W4387356823 workType "article" @default.